Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback